Loading...
•
Dec 31, 2023
ANI Pharmaceuticals Q4 2023 Earnings Report
ANI Pharmaceuticals reported a strong Q4 2023 with significant revenue growth, driven by the Rare Disease segment, particularly Cortrophin Gel, and issued 2024 guidance.
Key Takeaways
ANI Pharmaceuticals reported a strong fourth quarter and record full-year financial results for 2023. Q4 net revenues reached $131.7 million, a 39.7% increase year-over-year, with net income of $0.7 million and GAAP diluted earnings per share of $0.04. The Rare Disease business, led by Cortrophin Gel, saw substantial growth, and the company issued 2024 revenue guidance of $520 million to $542 million.
ANI Pharmaceuticals reported Q4 net revenues of $131.7 million, a 39.7% increase year-over-year.
Net income to common shareholders was $0.7 million, with GAAP diluted earnings per share of $0.04.
The Rare Disease business recorded Q4 net revenues of $41.7 million, reflecting a 137.3% year-over-year growth.
The company issued 2024 guidance with net revenues projected between $520 million and $542 million.
ANI Pharmaceuticals
ANI Pharmaceuticals
Forward Guidance
ANI Pharmaceuticals issued its full year 2024 guidance, projecting net revenues between $520 million and $542 million, adjusted non-GAAP EBITDA between $135 million and $145 million, and adjusted non-GAAP diluted earnings per share between $4.26 and $4.67. The guidance includes Cortrophin Gel net revenues of $170 million to $180 million, representing year-over-year growth of 52% to 61%.
Positive Outlook
- Net Revenue (Total Company) $520 million - $542 million
- Cortrophin Gel Net Revenue $170 million - $180 million, representing year-over-year growth of 52% to 61%
- Adjusted Non-GAAP EBITDA $135 million - $145 million
- Total company adjusted non-GAAP gross margin between 62% and 63%
- Between 19.3 million and 19.7 million shares outstanding
Challenges Ahead
- Adjusted Non-GAAP Diluted EPS $4.26 - $4.67, a decrease of (10)% - (8)%
- U.S. GAAP effective tax rate of between approximately 20.0% to 22.0%
- Estimated statutory tax rate of 26.0%
- Uncertainties and risks related to commercial success of Cortrophin Gel
- Potential disruptions from acquisitions and other investments